2.A case of isolated ACTH deficiency.
Seung Won CHOI ; Ki Up LEE ; Dong Wan SEO ; Ghi Su KIM ; Munho LEE
Journal of Korean Society of Endocrinology 1992;7(4):397-401
No abstract available.
Adrenocorticotropic Hormone*
3.Autonomously functioning thyroid nodules.
Young Kee SHONG ; Ki Up LEE ; Ghi Su KIM ; Munho LEE
Journal of Korean Society of Endocrinology 1992;7(2):121-126
No abstract available.
Thyroid Gland*
;
Thyroid Nodule*
4.Improvement of Metabolic Syndrom by Alpha-lipoic Acid.
Eun Hee KOH ; Woo Je LEE ; Min Seon KIM ; Joong Yeol PARK ; Ki Up LEE
Journal of Korean Society of Endocrinology 2004;19(3):267-273
No abstract available.
Thioctic Acid*
5.Effect of glipizide(Glyco@) treatment on glucose and lipid metaboli- sm in patients with type 2 diabetes mellitus
Ki Up LEE ; Jin Sook RYU ; Young Kee SHONG ; Munho LEE
Journal of the Korean Diabetes Association 1991;15(1):121-126
No abstract available.
Diabetes Mellitus, Type 2
;
Glucose
;
Humans
6.Simultaneous measurement of thyroid growth stimulating antibody and thyroid adenylate cyclase stimulating antibody using FRTL-5 cells in patients with Graves' disease.
Young Kee SHONG ; Dae Hyuk MOON ; Ki Up LEE ; Myung Hae LEE ; Munho LEE ; Bo Youn CHO ; Chang Soon KOH
Journal of Korean Society of Endocrinology 1991;6(1):17-24
No abstract available.
Adenylyl Cyclases*
;
Graves Disease*
;
Humans
;
Thyroid Gland*
7.Tuberculous abscess of the thyroid.
Seon Mee PARK ; Young Kee SHONG ; Ki Up LEE ; Ghi Su KIM ; Munho LEE ; Kun Choon PARK
Journal of Korean Society of Endocrinology 1992;7(2):149-152
No abstract available.
Abscess*
;
Thyroid Gland*
8.A case of osteoporosis associated with pernicious anemia.
Sang Wook KIM ; Seung Won CHOI ; Jung Shin LEE ; Joong Yeol PARK ; Ki Up LEE ; Ghi Su KIM
Journal of Korean Society of Endocrinology 1993;8(3):351-355
No abstract available.
Anemia, Pernicious*
;
Osteoporosis*
9.Changes in diurnal variation of thyrotropin in severe acutenonthyroidal illness.
Young Kee SHONG ; Jin Sook RYU ; Ki Up LEE ; Sang Sig CHEONG ; Youn Suck KOH ; Myung Hae LEE
Journal of Korean Society of Endocrinology 1991;6(4):342-347
No abstract available.
Thyrotropin*
10.Rosiglitazone Activates AMPK and Improves Non-Alcoholic Fatty Liver Disease in OLETF Rats.
Korean Diabetes Journal 2008;32(2):141-148
BACKGROUND: Insulin resistance is very common in patients with nonalcoholic fatty liver disease (NAFLD). Glitazones improve insulin sensitivity by acting as a selective agonist of the peroxisome proliferators -activated receptor gamma (PPAR gamma), and were shown to activate AMP-activated protein kinase (AMPK) in skeletal muscle and the liver. Glitazones were also shown to reduce hepatic lipogenesis. The aim of this study was to investigate whether the protective mechanism of rosiglitazone on NAFLD is associated with AMPK activation. METHODS: Twelve OLETF rats were divided into 2 groups (control, treatment, n = 6 each). LETO rats served as controls. At 35 weeks of age, treatment group received rosiglitazone 4 mg/kg daily for 3 days. Fasting plasma glucose, insulin, free fatty acid, lactate and triglycerides were measured. Liver tissues from each group were processed for histological and hepatic triglyceride content analysis and western blotting. RESULTS: Fasting plasma glucose, insulin and triglycerides levels were significantly lower in treatment group than in control group. Histologic examination disclosed decreased hepatic steatosis in treatment group. Hepatic triglyceride content was also decreased in treatment group. Sterol regulatory binding protein-1c (SREBP-1c) and fatty acid synthase (FAS) expression were increased and AMPK phosphorylation was reduced in OLETF rats compared with LETO rats, and these changes were reversed by rosiglitazone treatment. CONCLUSION: Rosiglitazone reduced hepatic steatosis in OLETF rats, and activated AMPK in the liver. These results suggest the role of AMPK activation in the protective action of rosiglitazone on NAFLD.
AMP-Activated Protein Kinases
;
Animals
;
Fasting
;
Fatty Acid Synthetase Complex
;
Fatty Liver
;
Glucose
;
Humans
;
Insulin
;
Insulin Resistance
;
Lactic Acid
;
Lipogenesis
;
Liver
;
Muscle, Skeletal
;
Peroxisome Proliferators
;
Phosphorylation
;
Plasma
;
Rats
;
Rats, Inbred OLETF
;
Thiazolidinediones
;
Triglycerides